TS
PNT

Thomas Steyer’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Thomas Steyer’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-626,322
Closed -$4.99M – 327
2022
Q1 		$4.99M Sell
626,322
-1,080,007
-63% -$6.86M 0.02% 183
2021
Q4 		$9.55M Sell
1,706,329
-583,671
-25% -$4.38M 0.05% 136
2021
Q3 		$17.6M Sell
2,290,000
-110,000
-5% -$1M 0.08% 111
2021
Q2 		$24.7M Buy
+2,400,000
New +$24.4M 0.1% 93

Other funds holding PNT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Thomas Steyer's PNT Position: Q2 2022 in Review

Thomas Steyer sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2022, closing a stake of 626,322 shares — an estimated $4.99M sold.

Thomas Steyer first reported a position in PNT in Q2 2021 and held it in 4 quarters. The position peaked at $24.7M in Q2 2021. 84 funds tracked by Wall St. Rank hold PNT as of Q2 2022.

  • Thomas Steyer reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Thomas Steyer sold 626,322 POINT Biopharma Global Inc. Common Stock shares in Q2 2022, an estimated $4.99M.
  • Thomas Steyer first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Thomas Steyer's POINT Biopharma Global Inc. Common Stock position peaked at $24.7M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2022.

Based on Farallon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.